Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-021-02632-y |
| _version_ | 1819198428947677184 |
|---|---|
| author | Hector Lafuente Ibon Jaunarena Eukene Ansuategui Arantza Lekuona Ander Izeta |
| author_facet | Hector Lafuente Ibon Jaunarena Eukene Ansuategui Arantza Lekuona Ander Izeta |
| author_sort | Hector Lafuente |
| collection | DOAJ |
| description | Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice. |
| first_indexed | 2024-12-23T03:00:18Z |
| format | Article |
| id | doaj.art-ce46e23cc8824a7db5073ff465a6cd69 |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-12-23T03:00:18Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-ce46e23cc8824a7db5073ff465a6cd692022-12-21T18:02:27ZengBMCStem Cell Research & Therapy1757-65122021-11-0112111710.1186/s13287-021-02632-yCell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysisHector Lafuente0Ibon Jaunarena1Eukene Ansuategui2Arantza Lekuona3Ander Izeta4Tissue Engineering Group, Biodonostia Health Research InstituteGynecology Oncology Unit, Donostia University HospitalClinical Epidemiology Group, Biodonostia Health Research InstituteGynecology Oncology Unit, Donostia University HospitalTissue Engineering Group, Biodonostia Health Research InstituteAbstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice.https://doi.org/10.1186/s13287-021-02632-yStem cellsLymphatic vasculatureLymphedemaRegenerationRegenerative medicineSystematic review |
| spellingShingle | Hector Lafuente Ibon Jaunarena Eukene Ansuategui Arantza Lekuona Ander Izeta Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis Stem Cell Research & Therapy Stem cells Lymphatic vasculature Lymphedema Regeneration Regenerative medicine Systematic review |
| title | Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
| title_full | Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
| title_fullStr | Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
| title_full_unstemmed | Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
| title_short | Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
| title_sort | cell therapy as a treatment of secondary lymphedema a systematic review and meta analysis |
| topic | Stem cells Lymphatic vasculature Lymphedema Regeneration Regenerative medicine Systematic review |
| url | https://doi.org/10.1186/s13287-021-02632-y |
| work_keys_str_mv | AT hectorlafuente celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT ibonjaunarena celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT eukeneansuategui celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT arantzalekuona celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT anderizeta celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis |